Revumenib by Syndax Demonstrates Effectiveness in Relapsed/Refractory KMT2A-Rearranged Acute Leukemia: ASH 2023 Findings Acute leukemia is a devastating blood cancer...
The holiday season is a time of joy, love, and celebration. It’s a time when families and friends come together...
Phase 1 Study of Beyond Cancer™ Successfully Completes Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or...
Bikepacking, the combination of backpacking and cycling, has gained popularity in recent years as a way to explore the great...
Cu-64 SAR-bisPSMA Administered to First Patient in Phase III Prostate Cancer Trial, Reports Drugs.com MedNews Prostate cancer is one of...
The FDA and US Government Declare State Approved Psychedelics Federally Illegal: Implications for Mental Health In recent years, there has...
Venture-Backed Startups, Including High-Quality Ones, Will Face Reserves Exhaustion by 2024: Insights from SaaStr In the fast-paced world of startups,...
The Food and Drug Administration (FDA) has recently expanded the utilization of Merck’s $1 billion cancer drug acquisition, marking a...
CymaBay Therapeutics, a biopharmaceutical company focused on developing innovative therapies for liver and metabolic diseases, has recently announced its submission...
A New Approach: Jaypirca’s Impact on Chronic Lymphocytic Leukaemia Treatment Chronic Lymphocytic Leukaemia (CLL) is a type of cancer that...
Kiromic BioPharma, a clinical-stage biotechnology company, has recently announced the administration of the initial dose to the first participant in...
How to Place Battery Strap Orders for Meta Resumes Quest 3 After Charging Issue The Meta Resumes Quest 3 is...
Targeted Therapy Demonstrates Promising Potential as a Final Lifeline for Acute Leukemia Patients Acute leukemia is a devastating form of...
Title: Promising Results from ORSERDU® (Elacestrant) Combination Studies in ER+, HER2- Metastatic Breast Cancer Patients Introduction: The 2023 San Antonio...
GSK’s Immuno-Oncology Treatment Receives Groundbreaking Approval in the EU In a groundbreaking development for cancer treatment, GlaxoSmithKline (GSK) has received...
